Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR) (CART-EGFR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01869166
Recruitment Status : Unknown
Verified September 2015 by Han weidong, Chinese PLA General Hospital.
Recruitment status was:  Recruiting
First Posted : June 5, 2013
Last Update Posted : September 29, 2015
Information provided by (Responsible Party):
Han weidong, Chinese PLA General Hospital

Brief Summary:

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous T cells may make the body build immune response to kill cancer cells.

PURPOSE: This clinical trial is to study genetically engineered lymphocyte therapy in treating patients with EGFR positive advanced/unresectable operation solid tumors, such as lung cancer, colorectal cancer,ovary cancer,cholangiocarcinoma,pancreatic cancer,renal carcinoma and other relapsed/metastatic tumors.

Condition or disease Intervention/treatment Phase
Advanced EGFR-positive Solid Tumors Biological: CART-EGFR Phase 1 Phase 2

Detailed Description:


I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-EGFR Lentivirus vector (referred to as CART-EGFR cells).

II. Determine duration of in vivo survival of CART-EGFR cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-EGFR CD3zeta:CD137 over time.


I. For patients with advanced, relapsed/metastatic cancers, measure anti-tumor response due to CART-EGFR cell infusions.

II. Estimate relative trafficking of CART-EGFR cells in tumor bed.

III. Determine if cellular or humoral host immunity develops against the murine anti-EGFR, and assess correlation with loss of detectable CART-EGFR (loss of engraftment).

IV. Determine the relative subsets of CART-EGFR T cells (Tcm, Tem, and Treg).

OUTLINE: Patients are assigned to 1 group according to order of enrollment.

Patients receive anti-EGFR-CAR (coupled with CD137 and CD3 zeta signalling domains)Lentivirus vector-transduced autologous T cells for 3-5 days in the absence of unacceptable toxicity.

After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 13 years.

Estimate relative trafficking of CART-EGFR cells in peripheral blood.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study of Chimeric EGFR Antigen Receptor-modified T Cells in Chemotherapy Refractory Advanced Solid Tumors
Study Start Date : May 2013
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : December 2017

Arm Intervention/treatment
Experimental: anti-tumor response of CART-EGFR Biological: CART-EGFR

Primary Outcome Measures :
  1. Occurrence of study related adverse events [ Time Frame: Until week 24 ]

Secondary Outcome Measures :
  1. Anti-tumor responses to CART-EGFR cell infusions [ Time Frame: up to 24 weeks ]

Other Outcome Measures:
  1. in vivo existence of CART-EGFR [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Chemotherapy refractory EGFR-positive non-small cell lung cancer, colorectal cancer with liver metastasis,and chemotherapy resistant or relapsed ovary cancerlung cancer,cholangiocarcinoma,pancreatic cancer,renal carcinoma and other relapsed/metastatic/unresectable operation tumors.the expression of EGFR in tumor is more than 50%.
  2. Relapsed patients after anti-EGFR using antibody or kinase inhibitor therapy.
  3. Patients must be 18 years of age or older.
  4. Patients must have an ECOG (Eastern Cooperative Oncology Group )performance status of 0-2.
  5. Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters:

    Absolute neutrophil count greater than 1500/mm3. Platelet count greater than 100,000/mm3. Hemoglobin greater than 10g/dl (patients may receive transfusions to meet this parameter).

    Total bilirubin < 1.5 times upper limits of normal. Serum creatinine less than or equal to 1.6 mg/ml or the creatinine clearance must be greater than 70 ml/min/1.73m(2).

  6. Seronegative for HIV antibody.
  7. Seronegative for active hepatitis B, and seronegative for hepatitis C antibody.
  8. Patients must be willing to practice birth control during and for four months following treatment.NOTE:women of child-bearing age must have evidence of negative pregnancy test.
  9. Patients must be willing to sign an informed consent.

Exclusion Criteria:

  1. Patients with life expectancy less than 12 months will be excluded.
  2. Patients with uncontrolled hypertension (> 160/95), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> New York Heart Association Class II), or myocardial infarction within 6 months of study will be excluded.
  3. Patients with any of the following pulmonary function abnormalities will be excluded: FEV(forced expiratory volume), < 30% predicted; DLCO (diffusing capacity of lung for carbon monoxide) < 30% predicted (post-bronchodilator); Oxygen Saturation less than 90% on room air.
  4. Patients with severe liver and kidney dysfunction or consciousness disorders will be excluded.
  5. Pregnant and/or lactating women will be excluded.
  6. Patients with active infections, including HIV, will be excluded, due to unknown effects of the vaccine on lymphoid precursors.
  7. Patients with any type of primary immunodeficiencies will be excluded from the study.
  8. Patients requiring corticosteroids (other than inhaled) will be excluded.
  9. Patients with history of T cell tumors will be excluded.
  10. Patients who are participating or participated any other clinical trials in latest 30 days will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01869166

Contact: weidong han, Dr. 86-10-13651392893
Contact: kaichao feng, Dr. 86-10-13811421950

China, Beijing
Chinese PLA General Hospital Recruiting
Beijing, Beijing, China, 100853
Contact: weidong han, Dr.    86-10-13651392893   
Contact: Kaichao Feng, Dr.    86-10-13811421950   
Principal Investigator: Yao Wang, Dr.         
Sponsors and Collaborators
Chinese PLA General Hospital
Study Chair: weidong han, Dr. Chinese PLA General Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Han weidong, Professor and Director, Chinese PLA General Hospital Identifier: NCT01869166     History of Changes
Other Study ID Numbers: CHN-PLAGH-BT-007
First Posted: June 5, 2013    Key Record Dates
Last Update Posted: September 29, 2015
Last Verified: September 2015

Keywords provided by Han weidong, Chinese PLA General Hospital:
chemotherapy and/or EGFR-antibody/kinase inhibitor therapy refractory solid tumors